| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | HD7; HD9; HD7b; HDAC; HDRP; MITR; HDAC7; HDAC7B; HDAC9B; HDAC9FL |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human HDAC9 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于HDAC9抗体的3篇参考文献，简要概括如下：
---
1. **文献名称**: *HDAC9 modulates vascular homeostasis through transcriptional control of smooth muscle cell plasticity*
**作者**: Zhou B, et al.
**摘要**: 该研究通过免疫组化和Western blot分析，揭示了HDAC9在血管平滑肌细胞表型转换中的关键作用。作者利用特异性HDAC9抗体证明其通过调控下游靶基因(如MYOCD)影响血管重塑，为动脉粥样硬化治疗提供新靶点。
---
2. **文献名称**: *Selective inhibition of HDAC9 by small molecules alters neuroinflammatory responses in microglia*
**作者**: Zhang Y, et al.
**摘要**: 研究通过ChIP-seq和免疫沉淀技术，结合HDAC9抗体，发现HDAC9特异性抑制剂可抑制小胶质细胞炎症通路(如NF-κB)，提示其在神经退行性疾病(如阿尔茨海默病)中的潜在治疗价值。
---
3. **文献名称**: *HDAC9 deficiency promotes tumor progression by dysregulating β-catenin in colorectal cancer*
**作者**: Li H, et al.
**摘要**: 利用HDAC9抗体进行组织芯片(TMA)分析，发现HDAC9低表达与结直肠癌转移相关。研究证实HDAC9通过去乙酰化β-catenin调控其稳定性，影响Wnt信号通路，从而抑制肿瘤侵袭。
---
以上文献均通过HDAC9抗体在实验(如Western blot、免疫组化或ChIP-seq)中验证其功能，涵盖心血管、神经及肿瘤领域。如需具体期刊信息或年份，可进一步补充检索。
Histone deacetylase 9 (HDAC9) is a class IIa member of the histone deacetylase family, which regulates gene expression by removing acetyl groups from lysine residues on histone proteins, leading to chromatin condensation and transcriptional repression. HDAC9 is uniquely characterized by its N-terminal regulatory domain and C-terminal catalytic domain, with tissue-specific expression in the heart, skeletal muscle, and brain. It interacts with transcription factors like MEF2 (myocyte enhancer factor-2), playing critical roles in cellular differentiation, apoptosis, and immune responses. Dysregulation of HDAC9 has been implicated in cancers, cardiovascular diseases, and neurological disorders, making it a focus of therapeutic research.
HDAC9 antibodies are essential tools for investigating its expression, localization, and molecular interactions. They are widely used in techniques such as Western blotting, immunohistochemistry, immunofluorescence, and chromatin immunoprecipitation (ChIP). These antibodies help identify HDAC9's involvement in pathological processes, such as promoting tumor progression via epigenetic silencing or contributing to atherosclerosis by modulating inflammatory pathways. Specific HDAC9 isoforms, generated through alternative splicing, further complicate its functional studies, necessitating antibodies that distinguish between variants. Validated HDAC9 antibodies also support drug discovery efforts, particularly in testing HDAC inhibitors targeting class IIa enzymes. Given its dual role as a epigenetic modifier and signaling scaffold, HDAC9 remains a key subject in understanding disease mechanisms and developing targeted therapies.
×
